PMID- 28841387
OWN - NLM
STAT- MEDLINE
DCOM- 20171211
LR  - 20240210
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 35
IP  - 34
DP  - 2017 Dec 1
TI  - Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued 
      Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled 
      Analysis of Randomized Phase II and III Trials.
PG  - 3807-3814
LID - 10.1200/JCO.2017.73.2289 [doi]
AB  - Purpose Approximately 40% of patients with advanced melanoma who received 
      nivolumab combined with ipilimumab in clinical trials discontinued treatment 
      because of adverse events (AEs). We conducted a retrospective analysis to assess 
      the efficacy and safety of nivolumab plus ipilimumab in patients who discontinued 
      treatment because of AEs. Methods Data were pooled from phase II and III trials 
      of patients who received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, every 3 weeks 
      for four doses, followed by nivolumab monotherapy 3 mg/kg every 2 weeks (N = 
      409). Efficacy was assessed in all randomly assigned patients who discontinued 
      because of AEs during the induction phase (n = 96) and in those who did not 
      discontinue because of AEs (n = 233). Safety was assessed in treated patients who 
      discontinued because of AEs (n = 176) at any time and in those who did not 
      discontinue because of AEs (n = 231). Results At a minimum follow-up of 18 
      months, median progression-free survival was 8.4 months for patients who 
      discontinued treatment because of AEs during the induction phase and 10.8 months 
      for patients who did not discontinue because of AEs ( P = .97). Median overall 
      survival had not been reached in either group ( P = .23). The objective response 
      rate was 58.3% for patients who discontinued because of AEs during the induction 
      phase and 50.2% for patients who did not discontinue. The vast majority of grade 
      3 or 4 AEs occurred during the induction phase, with most resolving after 
      appropriate management. Conclusion Efficacy outcomes seemed similar between 
      patients who discontinued nivolumab plus ipilimumab treatment because of AEs 
      during the induction phase and those who did not discontinue because of AEs. 
      Therefore, even after discontinuation, many patients may continue to derive 
      benefit from combination therapy.
FAU - Schadendorf, Dirk
AU  - Schadendorf D
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Wolchok, Jedd D
AU  - Wolchok JD
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Hodi, F Stephen
AU  - Hodi FS
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Chiarion-Sileni, Vanna
AU  - Chiarion-Sileni V
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Gonzalez, Rene
AU  - Gonzalez R
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Rutkowski, Piotr
AU  - Rutkowski P
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Grob, Jean-Jacques
AU  - Grob JJ
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Cowey, C Lance
AU  - Cowey CL
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Lao, Christopher D
AU  - Lao CD
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Chesney, Jason
AU  - Chesney J
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Robert, Caroline
AU  - Robert C
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Grossmann, Kenneth
AU  - Grossmann K
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - McDermott, David
AU  - McDermott D
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Walker, Dana
AU  - Walker D
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Bhore, Rafia
AU  - Bhore R
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Larkin, James
AU  - Larkin J
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
FAU - Postow, Michael A
AU  - Postow MA
AD  - Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, 
      Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering 
      Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. 
      Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel 
      Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico 
      Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; 
      Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of 
      Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Universite, Assistance 
      Publique Hopitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy 
      and Universite Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor 
      Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, 
      MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, 
      Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, 
      Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, 
      London, United Kingdom.
LA  - eng
GR  - 20265/CRUK_/Cancer Research UK/United Kingdom
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
DEP - 20170825
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
CIN - J Clin Oncol. 2017 Dec 1;35(34):3792-3793. PMID: 29048973
CIN - J Clin Oncol. 2018 Mar 1;36(7):722-723. PMID: 29337635
CIN - J Clin Oncol. 2018 Mar 1;36(7):720-721. PMID: 29337638
CIN - J Clin Oncol. 2018 Mar 1;36(7):721. PMID: 29337639
MH  - Antibodies, Monoclonal/administration & dosage/*adverse effects
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Databases, Factual
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ipilimumab/administration & dosage/*adverse effects
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Melanoma/*drug therapy/*mortality/pathology
MH  - Neoplasm Invasiveness/pathology
MH  - Neoplasm Staging
MH  - Nivolumab
MH  - Patient Safety/statistics & numerical data
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Skin Neoplasms/*drug therapy/*mortality/pathology
MH  - Statistics, Nonparametric
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Withholding Treatment
PMC - PMC5791828
EDAT- 2017/08/26 06:00
MHDA- 2017/12/12 06:00
PMCR- 2018/01/01
CRDT- 2017/08/26 06:00
PHST- 2017/08/26 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/08/26 06:00 [entrez]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 732289 [pii]
AID - 10.1200/JCO.2017.73.2289 [doi]
PST - ppublish
SO  - J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 
      2017 Aug 25.